Astellas Sees Surge in 9-Month Revenue on Xtandi Growth, US Market Recovery
To read the full story
Related Article
- Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets
October 31, 2024
- Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
- Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
- Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
- Astellas Slashes FY2023 Veozah Forecast as Vertical Start-Up Plan Stumbles
February 6, 2024
- Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
April 28, 2023
- Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
February 7, 2023
- Astellas’ Half-Year Revenue Up 17% on FX Boon; Xtandi US Sales Stall
November 2, 2022
- Astellas’ Earnings Hit by FX as Cost Rate Worsens on Overseas Inventories
August 2, 2022
- Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
- Astellas’ Half-Year Revenue Up Nearly 6% on Bullish Xtandi
November 1, 2021
- Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
August 2, 2021
- Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
- Astellas’ 9-Month Earnings Stumble on Celecox Generic Erosion, Sales Pact Terminations
February 1, 2021
- Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
November 2, 2020
- Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
August 5, 2020
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
BUSINESS
- KalVista Eyes Japan Debut with World’s 1st Oral On-Demand HAE Drug
March 14, 2025
- FDA Rejects Seikagaku’s Herniated Disk Drug
March 14, 2025
- Glaucoma Eye Drop Rocklatan Now Available in Singapore: Santen
March 14, 2025
- Pfizer Japan Files NDA for Tucatinib for HER2 Breast Cancer
March 14, 2025
- Mitsubishi Tanabe’s Oral Edaravone Filed in South Korea
March 14, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…